Kaposi's sarcoma: A 10-year experience with 248 patients at a single tertiary care hospital in Tanzania Cancer

被引：22
作者：
Chalya P.L. [1 ]
Mbunda F. [1 ]
Rambau P.F. [2 ]
Jaka H. [3 ]
Masalu N. [4 ]
Mirambo M. [5 ]
Mushi M.F. [5 ]
Kalluvya S.E. [3 ]
机构：
[1] Department of Surgery, Bugando Medical Centre, Mwanza
[2] Department of Pathology, Catholic University of Health and Allied Science-Bugando, Mwanza
[3] Department of Internal Medicine, Catholic University of Health and Allied Science-Bugando, Mwanza
[4] Department of Oncology, Bugando Medical Centre, Mwanza
[5] Department of Microbiology, Catholic University of Health and Allied Science-Bugando, Mwanza
来源：
BMC Research Notes | / 8卷 / 1期
关键词：
Acquired immunodeficiency syndrome; Clinicopathological; Human immunodeficiency virus; Kaposi's sarcoma; Tanzania; Treatment outcome;
D O I：
10.1186/s13104-015-1348-9
中图分类号：
学科分类号：
摘要：
Background: Kaposi's Sarcoma is the most common sarcoma and second most prevalent cancer seen in Tanzania. Little is known about Kaposi's sarcoma in our setting as there is paucity of recent published data regarding this condition. This study describes the clinicopathological pattern and treatment outcome of Kaposi's sarcoma at Bugando Medical Centre, a tertiary care hospital in northwestern Tanzania. Methods: This was a prospective study of histologically confirmed Kaposi's sarcoma that was conducted at Bugando Medical Center between July 2004 and June 2014. Results: A total of 248 patients (M:F = 1.4:1) representing 2.4 % of all malignancies during the study period were enrolled into the study. The median age at presentation was 36 years. Females were younger than males (p = 0.04). Out of 248 patients, 122 (49.2 %) were HIV positive. Of these, 46 (37.7 %) were males and 76 (62.3 %) females. AIDS-related Kaposi's sarcoma were younger than HIV negative Kaposi's sarcoma patients (p = 0.011). Median duration of symptoms was 6 months. Kaposi's sarcoma was the AIDS defining disease in 82 (67.2 %) patients while in the remaining 40 (32.8 %) it was diagnosed between 1 and 14 months after the initial diagnosis of AIDS. The lower limb was most frequently involved site in 28.9 % of patient. Females had more disseminated lesions compared with more localized lesions in the males (p = 0.001). The treatment modalities in this study included chemotherapy, radiotherapy, surgery and highly active antiretroviral therapy. Overall 126 (53.4 %) patients had significant improvement in quality of life at the end of 1 year follow up. Treatment related complication and mortality rates were 25.8 and 24.2 % respectively. Poor ACTG stage, CD4+ count <200 cells/μl, associated co-morbid illness, disseminated disease and poor adherent to chemotherapy were the significant independent factors associated with deaths (p < 0.001). Patient's follow-up was generally poor and data on long-term survivals were not available as more than two-thirds of patients were lost to follow up. Conclusion: Kaposi's sarcoma is the most common malignant vascular tumor and HIV/AIDS- related cancer in our region. There is an urgent need to develop health education programmes to enhance the understanding of this disease and how it spreads, particularly among the younger generation. © 2015 Chalya et al.
引用
收藏
相关论文
共 57 条
[51]  
Moore R.D., Keruly J.C., Chaisson R.E., Anemia and survival in HIV infection, J Acquir Immune Defic Syndr Hum Retrovirol, 19, pp. 29-33, (1998)
[52]  
Martellotta F., Berretta M., Vaccher E., Schioppa O., Zanet E., Tirelli U., AIDS-related Kaposi's sarcoma: State of the art and therapeutic strategies, Curr HIV Res, 7, pp. 634-638, (2009)
[53]  
Koon H.B., Fingleton B., Lee J.Y., Et al., Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma, J Acquir Immune Defic Syndr, 56, pp. 64-68, (2011)
[54]  
Makombe S.D., Harries A.D., Kwong-Leung Yu.J., Et al., Outcomes of patients with Kaposi's sarcoma who start antiretroviral therapy under routine programme conditions in Malawi, Trop Doct, 38, pp. 5-7, (2008)
[55]  
Nguyen H.Q., Amalia S.M., Kitahata M.M., Rompaey S.E., Wald A., Casper C., Persistent Kaposi sarcoma in the era of HAART: Characterizing the predictors of clinical response, AIDS, 22, pp. 937-945, (2008)
[56]  
Tirelli U., Bernardi D., Impact of HAART on the clinical management of AIDS-related cancers, Euro J Cancer, 37, pp. 1320-1324, (2001)
[57]  
Guadalupe M., Pollock B.H., Westbrook S., Et al., Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy, J Acquir Immune Defic Syndr, 56, pp. 83-90, (2011)
123456